Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Mark S Chapman & Jeffrey N Miner. (2011) Novel mitogen-activated protein kinase kinase inhibitors. Expert Opinion on Investigational Drugs 20:2, pages 209-220.
Read now
Read now
Patrick J. Eulitt, Margaret A. Park, Hamed Hossein, Nichola Cruikshanks, Chen Yang, Igor P. Dmitriev, Adly Yacoub, David T. Curiel, Paul B. Fisher & Paul Dent. (2010)
Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery
. Cancer Biology & Therapy 10:12, pages 1290-1305.
Read now
Read now
Mark A Feitelson, Marcia M Clayton, Helena MGPV Reis, Guoyi Wu & Eva Ping Lu. (2008) Pharmacotherapy of chronic viral hepatitis and hepatocellular carcinoma. Expert Opinion on Pharmacotherapy 9:13, pages 2233-2245.
Read now
Read now
B. Wang, H. Xu, Z. Q. Gao, H. F. Ning, Y. Q. Sun & G. W. Cao. (2008) Increased Expression of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization. Acta Radiologica 49:5, pages 523-529.
Read now
Read now
Articles from other publishers (48)
Yuewen Gao, Zhengwu Pan, Hongqi Li & Fei Wang. (2023) Antitumor Therapy Targeting the Tumor Microenvironment. Journal of Oncology 2023, pages 1-16.
Crossref
Crossref
Ashish Shah, Vaishali Patel & Ghanshyam Parmar. 2022. Phytoantioxidants and Nanotherapeutics. Phytoantioxidants and Nanotherapeutics
495
519
.
Paul Dent. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
250
261
.
Paul Dent. 2021. Reference Module in Biomedical Sciences. Reference Module in Biomedical Sciences.
Qian‐qing Wang, Xiang‐cui Guo, Li Li, Zhi‐hui Gao & Mei Ji. (2019) Treatment with metformin and sorafenib alleviates endometrial hyperplasia in polycystic ovary syndrome by promoting apoptosis via synergically regulating autophagy. Journal of Cellular Physiology 235:2, pages 1339-1348.
Crossref
Crossref
Ruixiao Li, Qi Li & Qing Ji. (2020) Molecular targeted study in tumors: From western medicine to active ingredients of traditional Chinese medicine. Biomedicine & Pharmacotherapy 121, pages 109624.
Crossref
Crossref
Peter Brenneisen & Andreas Reichert. (2018) Nanotherapy and Reactive Oxygen Species (ROS) in Cancer: A Novel Perspective. Antioxidants 7:2, pages 31.
Crossref
Crossref
Taiyang Liu, Jie Li, Xiuhua Wen, Zhang Hui & Gui Qi. (2016) Sorafenib improves the postoperative effect of early stage renal cell carcinoma. Oncology Letters 12:6, pages 4367-4370.
Crossref
Crossref
Daniel F. Camacho & Kenneth J. Pienta. 2015. Bone Cancer. Bone Cancer
647
655
.
Nicolas Penel, Isabelle Ray-Coquard, Christine Bal-Mahieu, Christine Chevreau, Axel Le Cesne, Antoine Italiano, Emmanuelle Bompas, Stéphanie Clisant, Brigitte Baldeyrou, Amélie Lansiaux, Yves-Marie Robin, Jacques-Olivier Bay, Sophie Piperno-Neumann, Jean-Yves Blay & Charles Fournier. (2013) Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial. Targeted Oncology 9:3, pages 273-277.
Crossref
Crossref
Daniel F. Camacho & Kenneth J. Pienta. (2014) A multi-targeted approach to treating bone metastases. Cancer and Metastasis Reviews 33:2-3, pages 545-553.
Crossref
Crossref
Guoyi Wu, Bo Liu, Yingjun Zhang, Jing Li, Alla Arzumanyan, Marcia M. Clayton, Raymond F. Schinazi, Zhaohe Wang, Siegfried Goldmann, Qingyun Ren, Faxhou Zhang & Mark A. Feitelson. (2013) Preclinical Characterization of GLS4, an Inhibitor of Hepatitis B Virus Core Particle Assembly. Antimicrobial Agents and Chemotherapy 57:11, pages 5344-5354.
Crossref
Crossref
Sandro Pasquali, Augustinus P. T. van der Ploeg, Simone Mocellin, Jonathan R. Stretch, John F. Thompson & Richard A. Scolyer. (2013) Lymphatic biomarkers in primary melanomas as predictors of regional lymph node metastasis and patient outcomes. Pigment Cell & Melanoma Research 26:3, pages 326-337.
Crossref
Crossref
Sun-Mi Yun, Kyung Hee Jung, Hyunseung Lee, Mi Kwon Son, Ju-Hyeon Seo, Hong Hua Yan, Byung Hee Park, Sungwoo Hong & Soon-Sun Hong. (2013) Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells. Cancer Letters 331:2, pages 250-261.
Crossref
Crossref
Ji-Wen Cheng & Yi Lv. (2013) New progress of non-surgical treatments for hepatocellular carcinoma. Medical Oncology 30:1.
Crossref
Crossref
JUNYONG ZHU, YUAN LI, CHAO GUAN & ZUHUA CHEN. (2012) Anti-proliferative and pro-apoptotic effects of 3,3′-diindolylmethane in human cervical cancer cells. Oncology Reports 28:3, pages 1063-1068.
Crossref
Crossref
Chandrajit P. Raut, Yves Boucher, Dan G. Duda, Jeffrey A. Morgan, Richard Quek, Marek Ancukiewicz, Johanna Lahdenranta, J. Paul Eder, George D. Demetri & Rakesh K. Jain. (2012) Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948). PLoS ONE 7:2, pages e26331.
Crossref
Crossref
Anthony D. William, Angeline C.-H. Lee, Kee Chuan Goh, Stéphanie Blanchard, Anders Poulsen, Ee Ling Teo, Harish Nagaraj, Chai Ping Lee, Haishan Wang, Meredith Williams, Eric T. Sun, Changyong Hu, Ramesh Jayaraman, Mohammed Khalid Pasha, Kantharaj Ethirajulu, Jeanette M. Wood & Brian W. Dymock. (2011)
Discovery of Kinase Spectrum Selective Macrocycle (16
E
)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer
. Journal of Medicinal Chemistry 55:1, pages 169-196.
Crossref
Crossref
Steven Simoens. (2011) Sorafenib for advanced renal cell carcinoma in real-life practice: a literature review. Health 03:02, pages 86-92.
Crossref
Crossref
E.M.L. Heath, K.L. Kaufman & R.I. Christopherson. (2011) B-RAF: A contributor to the melanoma phenotype. The International Journal of Biochemistry & Cell Biology 43:1, pages 29-32.
Crossref
Crossref
Gang Wei, Meifang Wang, Terry Hyslop, Ziqiu Wang & Brian I. Carr. (2010)
Vitamin K enhancement of sorafenib‐mediated HCC cell growth inhibition
in vitro
and
in vivo
. International Journal of Cancer 127:12, pages 2949-2958.
Crossref
Crossref
Gajanan S. Inamdar, SubbaRao V. Madhunapantula & Gavin P. Robertson. (2010) Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail. Biochemical Pharmacology 80:5, pages 624-637.
Crossref
Crossref
Margaret A. Park, Roland Reinehr, Dieter Häussinger, Christina Voelkel-Johnson, Besim Ogretmen, Adly Yacoub, Steven Grant & Paul Dent. (2010) Sorafenib Activates CD95 and Promotes Autophagy and Cell Death via Src Family Kinases in Gastrointestinal Tumor Cells. Molecular Cancer Therapeutics 9:8, pages 2220-2231.
Crossref
Crossref
Margaret A. Park, Clint Mitchell, Guo Zhang, Adly Yacoub, Jeremy Allegood, Dieter Häussinger, Roland Reinehr, Andrew Larner, Sarah Spiegel, Paul B. Fisher, Christina Voelkel-Johnson, Besim Ogretmen, Steven Grant & Paul Dent. (2010)
Vorinostat and Sorafenib Increase CD95 Activation in Gastrointestinal Tumor Cells through a Ca2+-
De novo
Ceramide-PP2A-Reactive Oxygen Species–Dependent Signaling Pathway
. Cancer Research 70:15, pages 6313-6324.
Crossref
Crossref
Corey Langer & Jean-Charles Soria. (2010) The Role of Anti–Epidermal Growth Factor Receptor and Anti–Vascular Endothelial Growth Factor Therapies in the Treatment of Non–Small-Cell Lung Cancer. Clinical Lung Cancer 11:2, pages 82-90.
Crossref
Crossref
D. Llobet, N. Eritja, A. Yeramian, J. Pallares, A. Sorolla, M. Domingo, M. Santacana, F.J. Gonzalez-Tallada, X. Matias-Guiu & X. Dolcet. (2010) The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. European Journal of Cancer 46:4, pages 836-850.
Crossref
Crossref
Robert D. Loberg & Kenneth J. Pienta. 2010. Bone Cancer. Bone Cancer
441
448
.
Herbert B. Newton. 2010. Glioblastoma. Glioblastoma
1
42
.
Gang Wei, Meifang Wang & Brian I. Carr. (2010) Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways. Journal of Cellular Physiology, pages n/a-n/a.
Crossref
Crossref
AeRang Kim, Frank M. Balis & Brigitte C. Widemann. (2009) Sorafenib and Sunitinib. The Oncologist 14:8, pages 800-805.
Crossref
Crossref
Teneille Walker, Clint Mitchell, Margaret A. Park, Adly Yacoub, Martin Graf, Mohamed Rahmani, Peter J. Houghton, Christina Voelkel-Johnson, Steven Grant & Paul Dent. (2009) Sorafenib and Vorinostat Kill Colon Cancer Cells by CD95-Dependent and -Independent Mechanisms. Molecular Pharmacology 76:2, pages 342-355.
Crossref
Crossref
Aditi Pandya Martin, Margaret A. Park, Clint Mitchell, Teneille Walker, Mohamed Rahmani, Andrew Thorburn, Dieter Häussinger, Roland Reinehr, Steven Grant & Paul Dent. (2009) BCL-2 Family Inhibitors Enhance Histone Deacetylase Inhibitor and Sorafenib Lethality via Autophagy and Overcome Blockade of the Extrinsic Pathway to Facilitate Killing. Molecular Pharmacology 76:2, pages 327-341.
Crossref
Crossref
Olga Martinho, António Gouveia, Marta Viana-Pereira, Paula Silva, Amadeu Pimenta, Rui Manuel Reis & José Manuel Lopes. (2009)
Low frequency of MAP kinase pathway alterations in
KIT
and
PDGFRA
wild-type GISTs
. Histopathology 55:1, pages 53-62.
Crossref
Crossref
Noah M. Hahn, Thomas Powles & Christopher J. Sweeney. (2009) Development of novel agents for bladder cancer. Update on Cancer Therapeutics 3:4, pages 160-169.
Crossref
Crossref
J. Andrew Carlson, Jeffrey S. Ross & Andrze J. Slominski. (2009) New techniques in dermatopathology that help to diagnose and prognosticate melanoma. Clinics in Dermatology 27:1, pages 75-102.
Crossref
Crossref
Hie-Won L. Hann & Mark Feitelson. 2010. Hepatocellular Carcinoma. Hepatocellular Carcinoma
235
257
.
Kenneth J. Pienta, Natalie McGregor, Robert Axelrod & David E. Axelrod. (2008) Ecological Therapy for Cancer: Defining Tumors Using an Ecosystem Paradigm Suggests New Opportunities for Novel Cancer Treatments. Translational Oncology 1:4, pages 158-164.
Crossref
Crossref
Alex J Eustace, John Crown, Martin Clynes & Norma O'Donovan. (2008) Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. Journal of Translational Medicine 6:1.
Crossref
Crossref
Olga Martinho, Alberto Gonçalves, Marise A.R. Moreira, Luiz F.J. Ribeiro, Geraldo S. Queiroz, Fernando C. Schmitt, Rui M. Reis & Adhemar Longatto-Filho. (2008) KIT activation in uterine cervix adenosquamous carcinomas by KIT/SCF autocrine/paracrine stimulation loops. Gynecologic Oncology 111:2, pages 350-355.
Crossref
Crossref
Jose L. Mauriz & Javier González-Gallego. (2008) Antiangiogenic Drugs: Current Knowledge and New Approaches to Cancer Therapy. Journal of Pharmaceutical Sciences 97:10, pages 4129-4154.
Crossref
Crossref
Mark A FeitelsonHelena MGPV ReisJingbo PanMarcy ClaytonBill SunN Lale Satiroglu-TufanZhaorui Lian. (2008) HBV X protein: elucidating a role in oncogenesis. Future Virology 3:5, pages 455-470.
Crossref
Crossref
Guo Zhang, Margaret A. Park, Clint Mitchell, Hossein Hamed, Mohamed Rahmani, Aditi Pandya Martin, David T. Curiel, Adly Yacoub, Martin Graf, Ray Lee, John D. Roberts, Paul B. Fisher, Steven Grant & Paul Dent. (2008) Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation. Clinical Cancer Research 14:17, pages 5385-5399.
Crossref
Crossref
Tomohiro Morita, Akiko Hori, Hiroto Narimatatsu, Tetsuya Tanimoto & Masahiro Kami. (2008) Current status of development of anticancer agents in Japan. International Journal of Hematology 87:5, pages 484-489.
Crossref
Crossref
SubbaRao V. Madhunapantula & Gavin P. Robertson. (2008) Is B-Raf a Good Therapeutic Target for Melanoma and Other Malignancies?. Cancer Research 68:1, pages 5-8.
Crossref
Crossref
Meenhard Herlyn, Ruth Halaban, Ze’ev Ronai, Lynn Schuchter, Marianne Berwick & Daniel Pinkel. (2007) Roadmap for New Opportunities in Melanoma Research. Seminars in Oncology 34:6, pages 566-576.
Crossref
Crossref
Jürgen Eberle, Bahtier M. Kurbanov, Amir M. Hossini, Uwe Trefzer & Lothar F. Fecker. (2007) Overcoming apoptosis deficiency of melanoma—Hope for new therapeutic approaches. Drug Resistance Updates 10:6, pages 218-234.
Crossref
Crossref
Raffaella Giavazzi, Maria Rosa Bani & Giulia Taraboletti. (2007) Tumor’host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds. Cancer and Metastasis Reviews 26:3-4.
Crossref
Crossref
Russel S. Taichman, Robert D. Loberg, Rohit Mehra & Kenneth J. Pienta. (2007) The evolving biology and treatment of prostate cancer. Journal of Clinical Investigation 117:9, pages 2351-2361.
Crossref
Crossref